EcoDrugPlus

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSPKIG00000024400
Gene Symbol: F2RL3
3 Cross references
191 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSPKIG00000016841
Gene Symbol: FYN
1 Cross references
132 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSPKIG00000019310
Gene Symbol: FYN
2 Cross references
259 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSPKIG00000008626
Gene Symbol: GPR119
2 Cross references
174 Possible Orthologues:

G1/s-Specific Cyclin-D1

Ensembl ID : ENSPKIG00000005626
Gene Symbol: LOC111851863
3 Cross references
233 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSPKIG00000006025
Gene Symbol: HCK
3 Cross references
202 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSPKIG00000006022
Gene Symbol: ITK
1 Cross references
207 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSPKIG00000013954
Gene Symbol: JAK1
1 Cross references
233 Possible Orthologues:

Janus Kinase 2

Ensembl ID : ENSPKIG00000020986
Gene Symbol: JAK2
3 Cross references
199 Possible Orthologues:

Kit Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSPKIG00000003235
Gene Symbol: KIT
3 Cross references
205 Possible Orthologues:

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSPKIG00000019449
Gene Symbol: KRAS
4 Cross references
202 Possible Orthologues:

Malt1 Paracaspase

Ensembl ID : ENSPKIG00000006637
Gene Symbol: MALT1
3 Cross references
195 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).